Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Indegene IPO
Indegene Ltd
₹14,190 /33 sharesMinimum Investment
Indegene IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 6 May ‘24 - 8 May ‘24 | ₹14,190 | 33 | ₹430 - ₹452 |
| Issue Size | IPO Doc |
|---|---|
| 1841.76Cr | RHP PDF |
Subscription rate
As of 08 May'24, 04:00 PM
| Qualified Institutional Buyers | 139.10x |
| Non-Institutional Investor | 49.79x |
| Retail Individual Investor | 6.94x |
| Employees | 5.42x |
| Total | 52.27x |
About Indegene
Founded in
1998
Managing director
Mr. Manish Gupta
Parent organisation
Indegene Ltd
Indegene Ltd IPO
https://www.youtube.com/watch?v=kjKRpoxL9OQ
Strengths & Financials of Indegene
Strengths
Risks
As of December 31, 2023, the company had 65 active clients. It provides solutions to these clients from its operation hubs situated across North America, Europe, and Asia.
As per the company’s RHP, it maintains long-standing relationships with major biopharmaceutical firms, including each of the 20 largest biopharmaceutical companies globally by revenue for the 2023 financial year.
The company meets its clients' needs through six operation hubs and 17 offices spread across North America, Europe, and Asia.
As per the company, it has completed several acquisitions since 2005, leveraging the synergies, networks, technologies, and talent pools of the acquired companies to its advantage.
The company reported revenue from operations of Rs. 966.27 cr, Rs. 1,664.6 cr and Rs. 2,306.13 cr in FY 2021, 2022 and 2023 respectively. For the same time periods, it reported Profit after tax of Rs. 185.68 cr, Rs. 162.81 cr and Rs. 266.09 cr respectively.
Since the company's business is entirely focused on the life sciences industry, and a significant portion of its revenue comes from certain large clients based in North America and Europe, its success and profitability are closely tied to factors impacting the life sciences industry and the ongoing relationships with these key clients.
The company relies on sub-contractors and third-party vendors to provide various services, including: (i) quality control services for pharmacovigilance; (ii) payroll services; (iii) software and web development; (iv) quality assurance; (v) medical information support; and (vi) campaign management.
The company, along with its subsidiaries and directors, is involved in ongoing legal proceedings. Any adverse outcomes in these proceedings could lead to liabilities or penalties, which might negatively impact the company's business and operating results.
The majority of the company’s revenues are derived from its Subsidiaries. Any disruptions in the operations of these Subsidiaries may adversely affect its business, financial condition, results of operations.
The company's international operations subject it to a range of challenges, including complex management issues, legal and tax risks, economic uncertainties, and fluctuations in exchange rates. These factors could have a detrimental impact on its business, financial condition, and operating results.
Indegene Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Indegene IPO
| Apply as | Price band | Apply Range |
|---|---|---|
| Regular | ₹430 - 452 | Upto ₹2 Lakh |
| Employee | ₹400 - 422 | Upto ₹2 Lakh |
| High Networth Individual | ₹430 - 452 | ₹2 - 5 Lakh |
For Indegene IPO, eligible investors can apply as Regular & Employee.